Asabys Partners
Venture capitalSeed–Series B · 12 people tracked
Investment thesis
Asabys seeks highly innovative and transformative technologies in science and medicine that can improve patients' lives. The firm integrates environmental, social, and governance considerations into its investment process and aligns with the United Nations Sustainable Development Goals. The firm operates as a collaborative partner to portfolio companies and benefits from financial backing under the EU's European Fund for Strategic Investments.
Source: firm website, verified Jul 21, 2026.
Team · 12 people
from the firm's website
What they invest in
from 1 of 31 portfolio companiesBiotech ×1Deep Tech ×1Digital Health ×1
HQs:Spain×1
Investments · 31 tracked
founders shown can be your intro pathSpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
R&D-driven biopharmaceutical company developing innovative medicines for central nervous system diseases
Frequently asked questions
- What stage does Asabys Partners invest at?
- Asabys Partners invests at the Seed, Series A, Series B stages.
- What sectors does Asabys Partners focus on?
- Asabys Partners focuses on Biotech, Deep Tech, Healthtech, Impact & Social Good, Medical Devices.
Similar investors
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
Lerer Hippeau is an early-stage venture capital firm focused on identifying and backing founders before they achieve prominence. The firm actively invests across multiple sectors including AI/ML, healthtech, fintech, enterprise software, and other emerging technology areas.